CT

CLINICAL TRIAL OF THE YEAR


This award recognises a European life science company that has realised a significant milestone in the clinic for a new therapy, drug, diagnostic tool, digital application or medical device.

Qualifying criteria

- Open to private or public biotech companies with a market cap of less than $10bn
- Clinical breakthrough to have been achieved in the period between 1 September 2018 and 1 September 2019

Judges will be paying particular attention to:

- Targeting of unmet medical need
- Key indicators / results / inflection points of clinical development
- Phase / speed / progress through clinical stage
- Innovative trial design / patient centric approach
- Outline of future timelines / value creation
 
 
 
BUY TICKETS AND TABLES
 
 

2019 FINALISTS

 

Alkermes

Alkermes plc, ALKS 3831, ENLIGHTEN-2, Phase III

Antipsychotic for the treatment of Schizophrenia
Galapagos

Galapagos, FINCH 1 and 3, Phase III

Methotrexate-Naïve Rheumatoid Arthritis
Imcyse

IMCYSE, IMCY-0098, Phase Ib

Treatment of Type 1 Diabetes
Novaliq

Novaliq GmbH, SEECASE NOV03, Phase II

Treatment of Dry Eye Disease (DED)
Rexgenero

Rexgenero, REX-001, Phase III

Ischemic Ulcer Immunotherapy

BUY TICKETS AND TABLES